Consolidated Planning Corp boosted its holdings in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 21.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,680 shares of the biopharmaceutical company’s stock after purchasing an additional 826 shares during the period. Consolidated Planning Corp’s holdings in Pfizer were worth $205,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Saxon Interests Inc. increased its stake in shares of Pfizer by 12.9% in the 3rd quarter. Saxon Interests Inc. now owns 8,309 shares of the biopharmaceutical company’s stock valued at $367,000 after buying an additional 951 shares during the period. JB Capital LLC increased its stake in shares of Pfizer by 3.5% in the 2nd quarter. JB Capital LLC now owns 146,908 shares of the biopharmaceutical company’s stock valued at $7,702,000 after buying an additional 5,027 shares during the period. Platte River Wealth Advisors LLC increased its stake in shares of Pfizer by 62.8% in the 3rd quarter. Platte River Wealth Advisors LLC now owns 12,717 shares of the biopharmaceutical company’s stock valued at $556,000 after buying an additional 4,905 shares during the period. Versor Investments LP increased its stake in shares of Pfizer by 59.7% in the 2nd quarter. Versor Investments LP now owns 68,200 shares of the biopharmaceutical company’s stock valued at $3,576,000 after buying an additional 25,500 shares during the period. Finally, Foundry Partners LLC increased its stake in shares of Pfizer by 10.0% in the 2nd quarter. Foundry Partners LLC now owns 485,705 shares of the biopharmaceutical company’s stock valued at $25,466,000 after buying an additional 44,260 shares during the period. 67.62% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research analysts have recently issued reports on the company. The Goldman Sachs Group upgraded Pfizer from a “neutral” rating to a “buy” rating and raised their price target for the stock from $47.00 to $60.00 in a research report on Tuesday, December 13th. StockNews.com assumed coverage on Pfizer in a research report on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Wells Fargo & Company lowered Pfizer from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $54.00 to $50.00 in a research report on Tuesday, January 17th. Credit Suisse Group set a $54.00 price target on Pfizer in a research report on Wednesday, January 18th. Finally, Bank of America lowered Pfizer from a “buy” rating to a “neutral” rating and set a $60.00 price target on the stock. in a research report on Wednesday, January 4th. Seven analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $53.00.
Pfizer Stock Performance
Pfizer (NYSE:PFE – Get Rating) last issued its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $1.78 EPS for the quarter, beating analysts’ consensus estimates of $1.47 by $0.31. The company had revenue of $22.64 billion for the quarter, compared to analyst estimates of $21.04 billion. Pfizer had a return on equity of 43.95% and a net margin of 29.81%. As a group, research analysts forecast that Pfizer Inc. will post 6.47 earnings per share for the current year.
Pfizer Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, March 3rd. Stockholders of record on Friday, January 27th will be issued a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.67%. This is a positive change from Pfizer’s previous quarterly dividend of $0.40. The ex-dividend date is Thursday, January 26th. Pfizer’s payout ratio is 30.77%.
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.